GlassScriptPhysician profile
Jonathan D Abramson
NPI 1194715276
$2,572.29
in general payments reported to CMS, 2019-2025
22 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $91.27 · 2021: $409 · 2022: $653 · 2023: $541 · 2024: $227 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.95 |
| Education | $233.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $351.89 | 2021-2022 | |
| Amgen INC. | $325.24 | 2019-2024 | Imdelltra (Amg 757), Lumakras |
| Astellas Pharma US INC | $181.98 | 2023 | |
| Lilly USA, LLC | $167.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $167.11 | 2021-2025 | Breyanzi |
| Celgene Corporation | $166.57 | 2020-2025 | Breyanzi, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $163.67 | 2019-2023 | Calquence |
| Karyopharm Therapeutics INC. | $162.90 | 2022-2023 | Xpovio |
| Jazz Pharmaceuticals INC. | $156.48 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.95 | 2019 | |
| Glaxosmithkline, LLC. | $115.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $97.05 | 2023 | Libtayo |
| Genentech USA, INC. | $68.57 | 2019 | |
| Portola Pharmaceuticals, LLC | $65.06 | 2019 | |
| Tesaro, INC. | $52.44 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $51.88 | 2021 | |
| Emd Serono, INC. | $43.80 | 2022 | |
| Smith+Nephew, INC. | $42.45 | 2023 | Grafix Pl |
| Array Biopharma INC | $23.00 | 2021 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.